Optiray 240 Injection

Ioversol
509mg/ml
TYCO HEALTHCARE / MALLINCKRODT INC
Pack size 50ml Glass Bottle
Dispensing mode POM
Source USA
AgentAL ZAHRAWI MEDICINES TRADING EST.
Retail Price 83.50 AED

Available as:

339mg/ml - Injection 509mg/ml - Injection 509mg/ml - Injection 636mg/ml - Injection 636mg/ml - Injection 678mg/ml - Injection 678mg/ml - Injection 678mg/ml - Injection 678mg/ml - Injection 741mg/ml - Injection 741mg/ml - Injection 741mg/ml - Injection 741mg/ml - Injection

Indications

Optiray 240 Injection is used for: Peripheral and coronary arteriography and left ventriculography, Intravenous excretory urography, Angiography

Adult Dose

Radiographic Body Imaging Usual: 50-150 mL IV OR 100-250 mL IV of (240 mg/mL) 25-75 mL IV OR 50-150 mL IV infusion; not to exceed 150 mL For 240 mg/mL: 35-100 mL IV OR 70-200 mL IV infusion; not to exceed 250 mL IV-DSA 30-50 mL IV, repeat PRN; NMT 250 mL Administration Central catheter: inject at 10-30 mL/sec Peripheral: inject at 12-20 mL/sec Flush vein immediately after injection w/ 20-25 mL of NS or D5W IV Urography 50-75 mL IV OR 75-100 mL IV of (240 mg/mL)

Child Dose

Radiographic Body Imaging 1-3 mL/kg IV (usual: 2 mL/kg) IV Urography 0.5-3 mL/kg IV (usual 1-1.5 mL/kg); not to exceed 3 mL/kg

Renal Dose

Administration

Contra Indications

Hypersensitivity.

Precautions

Diagnostic procedures which involve the use of iodinated intravascular contrast agents should be carried out under the direction of personnel skilled and experienced in the particular procedure to be performed. A fully equipped emergency cart, or equivalent supplies and equipment, and personnel competent in recognizing and treating adverse reactions of all types should always be available. Since severe delayed reactions have been known to occur, emergency facilities and competent personnel should be available for at least 30 to 60 minutes after administration. Lactation: not known, use caution

Pregnancy-Lactation

Pregnancy Postmarketing data with product use in pregnant women are insufficient to determine if there is risk of drug-associated adverse developmental outcomes; literature reports show that product crosses placenta and is visualized in digestive tract of exposed infants after birth; product crosses placenta and reaches fetal tissues in small amounts; in animal reproduction studies, no adverse developmental effects were observed following intravenous administration of ioversol to pregnant rats and rabbits at doses 0.35 and 0.71 times, respectively, the maximum recommended human dose Lactation There is no information about presence of product in human or animal milk, effects of drug on breastfed infant, or effects of drug on milk production; however, iodinated contrast agents are excreted unchanged in human milk in very low amounts with poor absorption from gastrointestinal tract of breastfed infant; the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for product and any potential adverse effects on breastfed infant from product or from underlying maternal condition; interruption of breastfeeding after exposure to iodinated contrast agents is not necessary because potential exposure of breastfed infant to iodine is small; however, a lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 8 hours (approximately 5 elimination half-lives) after product administration in order to minimize drug exposure to breast fed infant

Interactions

Adverse Effects

Side effects of Ioversol : Usually mild to moderate, of short duration and resolve spontaneously (without treatment). However, serious, life-threatening and fatal reactions, mostly of cardiovascular origin, have been associated with the administration of iodine-containing contrast media. Injections of contrast media are often associated with sensations of warmth and pain. In controlled double-blind clinical studies, significantly less warmth and pain were associated with the injection than with iothalamate meglumine, diatrizoate meglumine, and diatrizoate meglumine and diatrizoate sodium.

Mechanism of Action

Opacifies vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures until significant hemodilution occurs

Note

Optiray 240 509mg/ml Injection manufactured by TYCO HEALTHCARE / MALLINCKRODT INC. Its generic name is Ioversol. Optiray 240 is availble in United Arab Emirates. Farmaco UAE drug index information on Optiray 240 Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Ioversol :

Injection
Optiray 160 339mg/ml
TYCO HEALTHCARE / MALLINCKRODT INC
Injection
Optiray 240 509mg/ml
TYCO HEALTHCARE / MALLINCKRODT INC
Injection
Optiray 240 509mg/ml
TYCO HEALTHCARE / MALLINCKRODT INC
Injection
Optiray 300 636mg/ml
TYCO HEALTHCARE / MALLINCKRODT INC
Injection
Optiray 300 636mg/ml
TYCO HEALTHCARE / MALLINCKRODT INC